Tricida, Inc. Rings the Opening Bell
ABOUT THIS EVENT
Tricida, Inc. (Nasdaq: TCDA), a pharmaceutical company focused on the development and commercialization of its drug candidate, veverimer (TRC101), a non-absorbed, orally-administered polymer designed to treat metabolic acidosis in patients with CKD, visited the Nasdaq MarketSite in Times Square.
In honor of the occasion, Gerrit Klaerner, PhD, President & CEO, rang the Opening Bell.